Cell Death News and Research

RSS

Novel compound clears harmful protein, protects neurons in frontotemporal dementia models

New research from Washington University School of Medicine in St. Louis adds to growing evidence that helping brain cells break down and eliminate their own cellular waste is a promising treatment strategy for a variety of neurodegenerative diseases.

31 Mar 2026

Impaired lipid transport protein locks stressed cells into cellular limbo

When cells experience enough chronic stress, they can stop dividing permanently. In this state of cellular limbo, known as replicative senescence, cells remain alive but no longer proliferate.

31 Mar 2026

Study reveals ALDH2 vulnerability in APC-deficient colorectal cancer

A precision cancer strategy that selectively kills tumour cells while leaving healthy tissue intact may be within reach for the majority of colorectal cancer patients, according to new research published in Genes & Disease.

30 Mar 2026

Researchers identifiy a promising strategy to reverse pulmonary fibrosis

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it.

30 Mar 2026

APOE4 alters brain immunity and cognition differently in females and males

APOE4 drove sex-specific changes in meningeal immunity, lymphatic drainage, brain lipids, neuroinflammation, and cognition in mouse models, with females showing greater inflammatory and cognitive vulnerability. Suppressing innate immunity improved some cognitive outcomes in female E4/E4 mice but worsened them in male E4/E4 mice, underscoring the need for sex-tailored approaches.

29 Mar 2026

Copper-based agent complex kills cancer cells in a novel way

A copper-based agent complex kills cancer cells in a novel way. It receives its activation signal through light. It could help where existing chemotherapy treatments reach their limits.

26 Mar 2026

Study identifies rare genetic disorder linked to premature aging and cognition

Scientists at Sanford Burnham Prebys Medical Discovery Institute and an international team of collaborators have defined a new genetic disease marked by premature aging and deficits in brain function.

24 Mar 2026

Breakthrough research reshapes understanding of T cell immune responses

In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S P Hicks Endowed Professor of Pathology, and Marcin Cieslik, assistant professor of pathology, both from University of Michigan Rogel Cancer Center, discovered a novel way the immune system, specifically T-cells, attack their target cells, reshaping long-held assumptions in immunology and demonstrating direct implications for the field of cancer immunology and bone marrow transplantation.

24 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Targeting protein fragment may improve Huntington disease treatments

Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than treatments, now in clinical trials, that target the whole protein but leave this fragment intact, a new study in mice suggests.

18 Mar 2026

Lysosomal storage of drugs may influence cancer treatment outcomes

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others.

17 Mar 2026

Vitamin B2 metabolism helps cancer cells resist ferroptosis

A lack of vitamin B2 makes tumour cells more susceptible to a unique form of cell death. This was discovered by researchers at the Rudolf Virchow Centre at the University of Würzburg.

13 Mar 2026

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

13 Mar 2026

Photoreceptor cells can recover from early stages of cell death

Photoreceptors are specialized cells in the eye that convert light energy into neural signals.

11 Mar 2026

New catalog identifies dozens of plasma membrane repair proteins

In the evolutionary history of life, the ability of a cell to separate its inner world from the external environment was an important turning point.

10 Mar 2026

Enzyme helps maintain retinal progenitor cells during eye development

The retina is a thin layer of neural tissue at the back of the eye that detects light and converts it into signals, sent to the brain.

9 Mar 2026

STING agonists exert potent antitumor effects against nervous system tumors

The cGAS-STING signaling pathway has emerged as a major focus in cancer immunotherapy because it stimulates interferon production and enhances antitumor immune responses.

9 Mar 2026

Unmasking the hyperactive circuitry of early Alzheimer’s

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer's disease.

9 Mar 2026

A novel approach to improving survival in treatment-resistant cancers

Researchers at the National University of Singapore (NUS) have identified a protein called tyrosine phosphatase 1B (PTP1B) as a potential "switch" that can modulate a type of cancer cell death known as immunogenic cell death (ICD).

6 Mar 2026

Dual targeting strategy may improve treatment for resistant lung cancers

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don't respond to immunotherapy.

5 Mar 2026